

**EXHIBIT A**  
**CLAIMS WHICH WILL BE PENDING**  
**UPON ENTRY OF THE INSTANT AMENDMENT**  
**(filed February 28, 2001)**

**U.S. APPLICATION SERIAL NO. 09/724,620**  
**(ATTORNEY DOCKET NO. 9426-048)**

---

23. A method for treating or preventing cancer in an animal, said method comprising administering to the animal a therapeutically or prophylactically effective amount of one or more anti-C3b(i) antibodies.

24. A method for treating or preventing cancer in an animal, said method comprising administering to the animal a therapeutically or prophylactically effective amount one or more nucleic acid sequences encoding one or more anti-C3b(i) antibodies.

25. A method for treating or preventing cancer in an animal, said method comprising administering to the animal a therapeutically or prophylactically effective amount of one or more anti-C3b(i) antibodies and one or more antibodies immunospecific for a cancer cell antigen.

sub  
B2

26. A method for treating or preventing cancer in an animal, said method comprising administering to the animal a therapeutically or prophylactically effective amount one or more nucleic acid sequences encoding one or more anti-C3b(i) antibodies and one or more nucleic acid sequences encoding one or more antibodies immunospecific for a cancer cell antigen.

27. The method of Claim 23, 24, 25 or 26, wherein at least one of the anti-C3b(i) antibodies is immunospecific specific for C3b(i) linked to IgM or IgG bound to cancer cells.

28. The method of Claim 23, 24, 25 or 26, wherein at least one of the anti-C3b(i) antibodies is immunospecific for C3b(i) linked to proteins or lipids on cancer cells.

29. The method of Claim 23, 24, 25 or 26, wherein at least one of the anti-C3b(i) antibodies is a bispecific antibody which is immunospecific for C3b(i) and an effector cell receptor or antigen.

30. The method of Claim 29 in which the effector cell is a lymphocyte, monocyte, macrophage, dendritic cell, neutrophil, natural killer cell, or erythrocyte.

31. The method of Claim 30 in which the effector cell is an erythrocyte.

32. The method of Claim 29 in which the antigen is CR1, CR2, CR3, CR4, CD16, CD32, CD64, or CD89.

33. The method of Claim 23, 24, 25 or 26, wherein at least one of the anti-C3b(i) antibodies is a monoclonal antibody.

34. The method of Claim 33 in which the monoclonal antibody is a human or humanized monoclonal antibody.

35. The method of Claim 23, 24, 25 or 26 further comprising administering to the animal IgG enriched plasma.

36. The method of Claim 23, 24, 25 or 26 further comprising administering to the animal IgM enriched plasma.

37. The method Claim 23, 24, 25 or 26 further comprising administering to the animal one or more complement components.

38. The method of Claim 24 or 26 further comprising administering to the animal one or more nucleic acid sequences encoding one or more complement components.

39. The method of Claim 23 or 25 in which at least one of the anti-C3b(i) antibodies is conjugated to a therapeutic agent.

40. The method of Claim 35 further comprising administering to the animal one or more complement components.

41. The method of Claim 36 further comprising administering to the animal one or more complement components.

42. The method of Claim 35 further comprising administering IgM enriched plasma and one or more complement components.

43. The method of Claim 23 or 25 in which at least one of the anti-C3b(i) antibodies is conjugated to a detectable agent.

44. The method of Claim 23, 24, 25 or 26 further comprising administering to the animal plasma.

45. The method of Claim 23, 24, 25 or 26 in which the animal is a mammal.

46. The method of Claim 23, 24, 25 or 26 in which the animal is a human.



**EXHIBIT B**  
**CLAIMS WHICH WILL BE PENDING**  
**UPON ENTRY OF THE INSTANT AMENDMENT**  
**FILED MAY7, 2002**

**U.S. APPLICATION SERIAL NO. 09/724,620**

**(ATTORNEY DOCKET NO. 9426-048)**

**RECEIVED**  
MAY 15 2002  
TECH CENTER 1600186000

23. A method for treating or preventing cancer in an animal, said method comprising administering to the animal a therapeutically or prophylactically effective amount of one or more anti-C3b(i) antibodies.

(24.) A method for treating or preventing cancer in an animal, said method comprising administering to the animal a therapeutically or prophylactically effective amount one or more nucleic acid sequences encoding one or more anti-C3b(i) antibodies.

25. A method for treating or preventing cancer in an animal, said method comprising administering to the animal a therapeutically or prophylactically effective amount of one or more anti-C3b(i) antibodies and one or more antibodies immunospecific for a cancer cell antigen.

(26.) A method for treating or preventing cancer in an animal, said method comprising administering to the animal a therapeutically or prophylactically effective amount of one or more nucleic acid sequences encoding one or more anti-C3b(i) antibodies and one or more nucleic acid sequences encoding one or more antibodies immunospecific for a cancer cell antigen.

27. The method of Claim 25 or 26, wherein at least one of the anti-C3b(i) antibodies is immunospecific specific for C3b(i) linked to IgM or IgG bound to cancer cells.

28. The method of Claim 25 or 26, wherein at least one of the anti-C3b(i) antibodies is immunospecific for C3b(i) linked to proteins or lipids on cancer cells.

29. The method of Claim 25 or 26, wherein at least one of the anti-C3b(i) antibodies is a bispecific antibody which is immunospecific for C3b(i) and an effector cell receptor or antigen.
30. The method of Claim 29 in which the effector cell is a lymphocyte, monocyte, macrophage, dendritic cell, neutrophil, natural killer cell, or erythrocyte.
31. The method of Claim 30 in which the effector cell is an erythrocyte.
32. The method of Claim 29 in which the receptor or antigen is CR1, CR2, CR3, CR4, CD16, CD32, CD64, or CD89.
33. The method of Claim 25 or 26, wherein at least one of the anti-C3b(i) antibodies is a monoclonal antibody.
34. The method of Claim 33 in which the monoclonal antibody is a human or humanized monoclonal antibody.
35. The method of Claim 25 or 26 further comprising administering to the animal IgG enriched plasma.
36. The method of Claim 25 or 26 further comprising administering to the animal IgM enriched plasma.
37. The method Claim 25 or 26 further comprising administering to the animal one or more complement components.
38. The method of Claim 26 further comprising administering to the animal one or more nucleic acid sequences encoding one or more complement components.
39. The method of Claim 25 in which at least one of the anti-C3b(i) antibodies is conjugated to a therapeutic agent.

40. The method of Claim 35 further comprising administering to the animal one or more complement components.

41. The method of Claim 36 further comprising administering to the animal one or more complement components.

42. The method of Claim 35 further comprising administering IgM enriched plasma and one or more complement components.

43. The method of Claim 25 in which at least one of the anti-C3b(i) antibodies is conjugated to a detectable agent.

44. The method of Claim 25 or 26 further comprising administering to the animal plasma.

45. The method of Claim 25 or 26 in which the animal is a mammal.

46. The method of Claim 25 or 26 in which the animal is a human.

47. A method of treating cancer in an animal, said method comprising administering to said animal a therapeutically effective amount of an antibody immunospecific for C3b(i) covalently linked to IgM or IgG bound to cancer cells.

48. A method of treating cancer in an animal, said method comprising administering to said animal a therapeutically effective amount of an antibody immunospecific for C3b(i) covalently linked to proteins or lipids on cancer cells.

49. A method of treating cancer in an animal, said method comprising administering to said animal a therapeutically effective amount of an anti-C3b(i) antibody and an anti-CD20 antibody.

50. The method of Claim 25, wherein the cancer cell antigen is CD20, HER2 or PSMA.

51. The method of Claim 49, wherein the anti-C3b(i) antibody is a bispecific antibody which is immunospecific for C3b(i) and an effector cell receptor or antigen.

52. The method of Claim 51 in which the effector cell is a lymphocyte, monocyte, macrophage, dendritic cell, neutrophil, natural killer cell, or erythrocyte.

53. The method of Claim 52 in which the effector cell is an erythrocyte.

54. The method of Claim 51 in which the antigen is CR1, CR2, CR3, CR4, CD16, CD32, CD64, or CD89.

55. The method of Claim 47, 48 or 49, wherein the anti-C3b(i) antibody is a monoclonal antibody.

56. The method of Claim 55 in which the monoclonal antibody is a human or humanized monoclonal antibody.

57. The method of Claim 47 or 48 further comprising administering to the animal IgG or IgM enriched plasma.

58. The method Claim 47 or 48 further comprising administering to the animal one or more complement components.

59. The method of Claim 47, 48 or 49 in which the anti-C3b(i) antibody is conjugated to a therapeutic agent.

60. The method of Claim 57 further comprising administering to the animal one or more complement components.

61. The method of Claim 47 or 48 further comprising administering to the animal plasma.

62. The method of Claim 47, 48 or 49 in which the animal is a mammal.

63. The method of Claim 62 in which the mammal is a human.
64. The method of Claim 25, wherein at least one of the anti-C3b(i) antibodies is 3E7 produced by the hybridoma deposited with the ATCC as Accession No. PTA-4090.
65. The method of Claim 47, 48 or 49, wherein the anti-C3b(i) antibody is 3E7 produced by the hybridoma deposited with the ATCC as Accession No. PTA-4090.
66. The method of Claim 49, wherein the anti-CD20 antibody is rituximab.
67. The method of Claim 49, wherein the anti-C3b(i) antibody is 3E7 produced by the hybridoma deposited with the ATCC as Accession No. PTA-4090 and the anti-CD20 antibody is rituximab.
68. The method of Claim 49, wherein the anti-C3b(i) antibody is immunospecific for C3b(i) covalently linked to IgM or IgG bound to cancer cells.
69. The method of Claim 49, wherein the anti-C3b(i) antibody is immunospecific for C3b(i) covalently linked to proteins or lipids in cancer cells.
70. The method of Claim 47 or 48, further comprising administering to the animal one or more purified complement components.
71. The method of claim 47 or 48, further comprising administering plasma to the animal.